Hemangioma

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

Retrieved on: 
Jeudi, mai 9, 2024
AXIN1, Research, Partnership, Clostridioides difficile infection, Development, IND, DeepMind, NVIDIA, Biomarker, Drug discovery, Tempus, Pharmacokinetics, Map, ADME, Machine learning, Software, Appetite, Roche, APC, Infection, Neurofibromatosis type II, CCM, Transcriptome, Safety, Johnson & Johnson, Neuroscience, RNA, Artificial intelligence, FAP, Data science, Therapy, Translation, Chemistry, RBM39, Biology, Clinical trial, LILAC, NF2, University of Oxford, Recurrence, Computational biology, Hemangioma, Administration, Patient, Strategy, Trial of the century, Pharmaceutical industry

L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.

Key Points: 
  • L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.
  • Revenue: Total revenue was $13.8 million for the first quarter of 2024, compared to $12.1 million for the first quarter of 2023.
  • Research and Development Expenses: Research and development expenses were $67.6 million for the first quarter of 2024, compared to $46.7 million for the first quarter of 2023.
  • Net Loss: Net loss was $91.4 million for the first quarter of 2024, compared to a net loss of $65.3 million for the first quarter of 2023.

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Vendredi, mars 8, 2024
Graviton, Epilepsy, Pharmacy technician, CCM, Research, Transcranial magnetic stimulation, DS, Neuron, Vigabatrin, LGS, Psychosis, Biomarker, Element, Ligand Pharmaceuticals, Lennox–Gastaut syndrome, Patient, Acceleration, Medicine, Status epilepticus, Dravet syndrome, ROCK2, KCC2, Hemangioma, IND, Seizure, Pharmaceutical industry

In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.

Key Points: 
  • In addition, Takeda is expected to read out results from two pivotal Phase 3 studies evaluating soticlestat.
  • Of these potential future payments, Ovid sold a 13% interest to Ligand Pharmaceuticals for $30 million in October 2023.
  • Financial runway: Ovid anticipates its cash runway will support operations and clinical development programs into the first half of 2026.
  • Ovid also anticipates several events for its current pipeline programs and clinical results for soticlestat from Takeda in 2024.

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Mardi, février 27, 2024
FAP, Senior, Research, FPI, Chemistry, Neuroscience, AXIN1, Part, Death, LLM, Software as a service, Hemangioma, Genetics, Cancer, Software, Letter, Business operations, Data, Matchmaker, APC, Machine learning, Real space, Biology, Development, Partnership, Therapy, Enamine, CCM, Myrexis, Library, Drug discovery, Safety, Biomarker, Clinical trial, IND, Clostridioides difficile infection, Roche, NF2, Biotechnology, Neurofibromatosis type II, Trial of the century, LILAC, Disease, Myriad Genetics, Administration, Pharmaceutical industry

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.

Key Points: 
  • SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
  • Research and Development Expenses: Research and development expenses were $69.5 million for the fourth quarter of 2023, compared to $44.0 million for the fourth quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $30.5 million for the fourth quarter of 2023 compared to $19.8 million for the fourth quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the fourth quarter of 2023, compared to a net loss of $57.5 million for the fourth quarter of 2022.

Neurelis to Host Virtual Pipeline Update to Discuss Advancements Addressing Unmet Needs in Neuroscience on March 7, 2024

Retrieved on: 
Lundi, février 26, 2024
FACS, Master of Science, ROCK, Olanzapine, University, Patient, MPH, New York Medical College, Hemangioma, Doctor of Psychology, Pharmaceutical industry

The investor call will be held virtually on Thursday, March 7, 2024 at 10:30 AM ET.

Key Points: 
  • The investor call will be held virtually on Thursday, March 7, 2024 at 10:30 AM ET.
  • To register, click here.
  • NRL-1004, an investigational nasal spray formulation of olanzapine and Neurelis proprietary Intravail® technology, for the treatment of acute agitation episodes, featuring Leslie Lucien Citrome, MD, MPH (New York Medical College, SUNY Upstate Medical University, Icahn School of Medicine at Mount Sinai).
  • A live question and answer session will follow the formal presentations of both segments.

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Jeudi, novembre 9, 2023
Research, Bayer, IND, Clostridioides difficile infection, Ovarian cancer, Hemangioma, FAP, Therapy, H100, Foundation models, Genetics, PB, SALT, Exercise, Software, Development, NF2, Pharmacokinetics, APC, NVIDIA, Clinical trial, Biology, Drug discovery, CCM, Partnership, Machine learning, Recursion, Meningioma, Personalized medicine, Benchmarking, LILAC, AXIN1, Genentech, Safety, Chemistry, Patient, Biotechnology, Map, Administration, Video game, Pharmaceutical industry, Fine chemical, Tempus

Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $29.2 million for the third quarter of 2023, compared to $19.5 million for the third quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the third quarter of 2023, compared to a net loss of $60.4 million for the third quarter of 2022.
  • Net Cash: Net cash used in operating activities was $72.9 million for the third quarter of 2023, compared to net cash used in operating activities of $54.5 million for the third quarter of 2022.

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Vendredi, novembre 3, 2023
Graviton, MB, KCC2, Element, Research, ROCK2, IND, TMS, Seizure, Neuron, IV, Dravet syndrome, Ligand Pharmaceuticals, SAD, Lennox–Gastaut syndrome, Development, Epilepsy, In vivo magnetic resonance spectroscopy, MRS, Transcranial magnetic stimulation, EEG, Status epilepticus, Hemangioma, Pharmaceutical industry, Takeda, Ligand

The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.

Key Points: 
  • The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.
  • General and administrative expenses were $6.8 million for the three months ended September 30, 2023, as compared to $7.6 million for the same period in 2022.
  • The decrease reflects the impact of headcount reductions conducted as part of organizational changes made in the first half of 2023.
  • Total operating expenses were $12.1 million for the three months ended September 30, 2023, as compared to $12.8 million for the same period last year.

The Vbeam 595 nm Pulsed Dye Laser, a Recognized Gold Standard for Vascular Treatment, Receives a Ground-Breaking FDA Clearance for the Treatment of Port Wine Stains and Hemangiomas in the Pediatric Population - the First Clearance of its Kind.

Retrieved on: 
Mercredi, juin 28, 2023
Partnership, JAMA Dermatology, Life, Neuraxial blockade, IH, Sun, PDL, Skin, IHS, Multimedia, Hemangioma, Dermatology, Incidence, Hospital, Physician, Candela Corp, Growth, Heat, FDA, PWS, Safety, Treatment, Pharmaceutical industry, Nursing, Medical device, Laser, Medicine, Patient

"Since that time, the focus of my clinical research and clinical practice has been the treatment of port wine stains and hemangiomas in infants and children.

Key Points: 
  • "Since that time, the focus of my clinical research and clinical practice has been the treatment of port wine stains and hemangiomas in infants and children.
  • "5
    "The new Vbeam 595 nm PDL clearance adds to the already impressive capabilities of this platform.
  • *Candela Vbeam Family of Pulsed Dye Lasers (Vbeam Prima, Vbeam Perfecta) FDA 510(k) Premarket Notification [K230990], June, 2023.
  • Pulsed Dye Laser at Subpurpuric Settings for the Treatment of Pulsed Dye Laser-Induced Ecchymoses in Patients With Port-Wine Stains.

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

Retrieved on: 
Mercredi, juin 28, 2023
Columbia University, SAB, Seizure, Postdoctoral researcher, Epilepsy, GABA, Pain disorder, Meg, Corporate Affairs, Doctor of Philosophy, MB, Rockefeller University, CSO, G&A, Research, CMO, CNS, GlaxoSmithKline Pharmaceuticals, Thought, Retirement, Syneos Health, ROCK2, Hemangioma, Vertex Pharmaceuticals, KCC2, Medical device, Pharmaceutical industry, Management

“We are excited as Zhong and Manoj respectively assume research and development leadership of Ovid’s focused pipeline of potential first-in-class and best-in-class CNS programs,” said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.

Key Points: 
  • “We are excited as Zhong and Manoj respectively assume research and development leadership of Ovid’s focused pipeline of potential first-in-class and best-in-class CNS programs,” said Jeremy Levin, D. Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics.
  • Prior to joining Ovid, Dr. Zhong served in senior leadership and scientific roles at Generation Bio, Wave Life Sciences, Vertex Pharmaceuticals, and GlaxoSmithKline Pharmaceuticals.
  • Dr. Zhong will partner closely with Dr. Manoj Malhotra who is taking on an expanded role as Chief Medical Officer.
  • In addition to deepening its bench of scientific leadership, Ovid expanded the role of Meg Alexander to the position of Chief Strategy Officer.

Lillian Brands Reveal Private Foundation Introduction Event, Leveraging the Power of Lillian Finance’s Cryptocurrency and Medical Blockchain to Save Children’s Lives

Retrieved on: 
Jeudi, mai 25, 2023
Technology, Health, Family, Blockchain, Consumer, Surgery, Professional Services, Other Philanthropy, Philanthropy, Children, General Health, Fund Raising, Cryptocurrency, Foundation, Partnership, LBF, Friends, Research, Tampa Bay, The Don CeSar, Lilly, Patient, Gravity anomaly, Hemangioma, Genetic testing, Bay, Hospital, Pharmaceutical industry, Nursing

Together, Lillian Brands aims to harness the power of decentralized finance to forever change and enhance the impact within the non-profit sector and medical healthcare industry.

Key Points: 
  • Together, Lillian Brands aims to harness the power of decentralized finance to forever change and enhance the impact within the non-profit sector and medical healthcare industry.
  • "Our team is eager to announce the world’s first medical blockchain consensus and are excited that all products will contribute to funding our philanthropic endeavors through the Lillian Bay Foundation.
  • The Lillian Bay Foundation (LBF), founded in 2022, is the first private foundation leveraging the power of cryptocurrency and blockchain technology to support the medical needs of children.
  • Lillian Brands kick-off mixer will introduce attendees to the work of the foundation and finance - cryptocurrencies and medical blockchain.

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
Lundi, mai 8, 2023
Acceleration, PK, Hemangioma, Partnership, NF2, Therapy, Proxy statement, AXIN1, Roche, Clinical trial, Pharmacokinetics, Intelligence, Research, FAP, History, Genentech, SALT, Chemistry, Development, Bayer, CCM, Patient, Administration, Machine learning, Map, DMPK, Drug discovery, Biology, Entrepreneurship, ESG, APC, Trial of the century, Growth, Ovarian cancer, IND, RBM39, Safety, Software, Pharmaceutical industry, Video game, Rare-earth element, Cyclica, Recursion

Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.

Key Points: 
  • Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.
  • Revenue: Total revenue was $12.1 million for the first quarter of 2023, compared to $5.3 million for the first quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $46.7 million for the first quarter of 2023, compared to $32.4 million for the first quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.9 million for the first quarter of 2023, compared to $21.1 million for the first quarter of 2022.